Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect
Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics. The post Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect appeared first on MedCity News.
Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics.
The post Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect appeared first on MedCity News.
